Mankind Pharma Ltd Half Yearly Results

2,586.45
(-1.11%)
Dec 6, 2024|03:31:22 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Sept-2024Mar-2024Sept-2023Mar-2023Sept-2022

Gross Sales

5,969.93

5,048.05

5,286.72

4,143.6

4,605.84

Excise Duty

0

0

0

0

0

Net Sales

5,969.93

5,048.05

5,286.72

4,143.6

4,605.84

Other Operating Income

0

0

0

0

0

Other Income

216.51

169.27

126.8

89.78

51.21

Total Income

6,186.44

5,217.32

5,413.52

4,233.38

4,657.04

Total Expenditure

4,438.13

3,850.45

3,949.26

3,289.88

3,558.92

PBIDT

1,748.31

1,366.87

1,464.26

943.51

1,098.12

Interest

18.01

18.57

14.96

17.92

26.55

PBDT

1,730.3

1,348.3

1,449.3

925.59

1,071.57

Depreciation

213.36

214.41

183.84

169.31

156.61

Minority Interest Before NP

0

0

0

0

0

Tax

306.83

185.72

306.86

166.01

161.55

Deferred Tax

8.16

11.77

-46.77

0.85

33.16

Reported Profit After Tax

1,201.95

936.4

1,005.37

589.42

720.26

Minority Interest After NP

11.99

11.4

17.47

19.83

7.99

Net Profit after Minority Interest

1,189.96

925

987.9

569.59

712.27

Extra-ordinary Items

0

0

0

0

0

Adjusted Profit After Extra-ordinary item

1,189.96

925

987.9

569.59

712.27

EPS (Unit Curr.)

29.7

23.09

24.66

14.22

17.78

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

40.06

40.06

40.06

40.06

40.06

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

29.28

27.07

27.69

22.77

23.84

PBDTM(%)

-

-

-

-

-

PATM(%)

20.13

18.54

19.01

14.22

15.63

Mankind Pharma: Related NEWS

Mankind Pharma Sees 30% Profit Surge in Q2
6 Nov 2024|10:12 PM

Revenue from operations grew by 13.6% YoY, totaling ₹3,076.5 Crore, up from ₹2,708.1 Crore in Q2 of the previous fiscal.

Read More
Top stocks for today - 6th November 2024
6 Nov 2024|08:08 AM

Here are some of the stocks that may see significant price movement today: Dr Reddy’s, Hindustan Zinc, Titan Company, etc.

Read More
Top stocks for today - 24th October 2024
24 Oct 2024|08:15 AM

Here are some of the stocks that may see significant price movement today: Escorts Kubota, Infosys, Mahindra & Mahindra, etc.

Read More
CCI greenlights Mankind Pharma's Rs 13,630 crore takeover of Bharat Serums
3 Oct 2024|11:02 AM

Mankind announced in July that it would purchase the whole stake in Bharat Serums and Vaccines.

Read More
Top 10 stocks for today – 3rd October 2024
3 Oct 2024|09:07 AM

Here are some of the stocks that may see significant price movement today: Suzlon Energy, Aurobindo Pharma, Coal India, etc.

Read More
Top 10 stocks for today – 1st October 2024
1 Oct 2024|08:17 AM

Here are some of the stocks that may see significant price movement today: Tata Power, India Glycols, Jindal Stainless, etc.

Read More
Mankind Pharma board approves ₹10,000 Crore fund raise
30 Sep 2024|07:41 PM

The company will offer commercial papers on the BSE in numerous tranches ranging from three to twelve months

Read More
Mankind Pharma Announces NCD Fundraising Initiative
23 Sep 2024|01:56 PM

This strategic move is intended to streamline Mankind Pharma’s operations, enabling greater focus on its core pharmaceutical business.

Read More
Mankind Pharma Transfers OTC Business to Subsidiary in Strategic Realignment
4 Sep 2024|10:21 AM

The transfer is in line with Mankind Pharma's previously announced strategy on April 2, aiming to enhance operational efficiency by consolidating the OTC business under MCPPL.

Read More
Mankind Pharma targets ₹9,000 crore debt for BSV deal
3 Sep 2024|12:25 PM

When the acquisition was announced, the business stated that it will be paid by internal accruals as well as a combination of debt and stock.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp